@article{ref1,
title="The Use of Selective Serotonin Reuptake Inhibitors in Pregnancy",
journal="Journal of obstetrics and gynaecology Canada",
year="2004",
author="Wen, S.W. and Walker, M.",
volume="26",
number="9",
pages="819-822",
abstract="OBJECTIVE: To provide an update of literature on the safety of using selective serotonin reuptake inhibitors (SSRIs) during pregnancy.<br><br>METHODS: MEDLINE was searched for English-language papers published from 1985 to 2003 on human studies of SSRIs, using the key words &quot;serotonin reuptake inhibitors,&quot; &quot;citalopram,&quot; &quot;fluoxetine,&quot; &quot;fluvoxamine,&quot; &quot;paroxetine,&quot; and &quot;sertraline&quot;. <br><br>RESULTS: The literature search yielded 12 338 publications. Previous studies on the safety of SSRIs in pregnancy were often based on small samples from medical centres, with het¬erogeneous design and outcome ascertainment methods, and had yielded inconsistent results. Consequently, the manage¬ment of pregnant women with depression poses challenges to clinicians who are hesitant to prescribe anti-depression drugs, including SSRIs, because of concern about potential risks to the fetuses. Failure to adequately treat maternal depression can lead to progressively worsening depression that greatly compromises maternal-fetal health and can impair bonding and childcare in the postpartum period.<br><br>CONCLUSIONS: Because of the uncertainty regarding the safety of SSRI use during pregnancy, consultation with specialists expe¬rienced in treating depression may be helpful when treating pregnant women with SSRIs. Large-scale, population-based studies to comprehensively assess the safety of SSRIs in preg¬nancy are needed. © 2004.<p /><p>Language: en</p>",
language="en",
issn="1701-2163",
doi="10.1016/S1701-2163(16)30155-4",
url="http://dx.doi.org/10.1016/S1701-2163(16)30155-4"
}